Mycophenolate Case Study

The Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new anticancer agent, in experimental animals.
The pharmacokinetics of a new anti-tumor agent i.e. ethyl o- [N-(p- carboxy phenyl)- carbamoyl] Mycophenolate (CAM) was studied in mice by using 14 c-labeled CAM and also metabolic differences were studied in species like rats, mice, rabbits, guinea pigs & dogs. The absorption of CAM was rapid from the gastrointestinal tract of the animals, mice compared to other animals. Due to the concentration of radioactivity two peaks are observed in the plasma of mice which reflects the concentration of metabolites in
The cellcept® IV solution was characterized by invitro in order to determine the benefits of the suspension of Mycophenolate mofetil over its solution form. The results have shown that aerosolization performance of both formulations were excellent. 24 hour single dose, pharmacokinetic studies followed by the inhalation both formulations and oral cellcept® administration were performed in rats. Mycophenolate mofetil was rapidly and completely metabolized into the active metabolite by oral drug administration where as partial and slow metabolism was observed by pulmonary drug administration. Hence the results have shown that inhaled Mycophenolate mofetil suspension form was displayed well favourable pharmacokinetic data than that of inhaled cellcept® IV solution
For systemic steroids, the Mycophenolate mofetil has been reported effectively as an adjuvant. The combination is very beneficial as steroids helps in minimizing the toxicities by its sparing effect and the Mycophenolate mofetil is be neficial in elevating the immunosuppressive effect. But, in case of PV refractory period, its effect was not worked out properly. They were used the combination of Mycophenolate mofetil (1g daily dose) and the systemic steroids in case of three Indian patients affecting with pemphigus vulgaris and were resistant to the monotherapy of systemic steroids or its combination with azathioprine. However, in this study it was conclude that the Mycophenolate mofetil was served as an effective adjuvant with less or minimal side-effects in treatment of the resistant